LR/mBCa: dual HER2-blockade plus taxane does well in PERUSE

  • Bachelot T & al.
  • Ann Oncol
  • 23 Feb 2019

  • curated by Miriam Davis, PhD
  • Univadis Clinical Summaries
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Takeaway

  • Preliminary results from the PERUSE trial find that front-line dual blockade with pertuzumab and trastuzumab plus a taxane is safe and effective for human epidermal growth factor receptor 2 (HER2)-positive locally recurrent (LR) or metastatic breast cancer (mBCa).
  • Docetaxel, paclitaxel, and nab-paclitaxel were similarly effective with different safety profiles.

Why this matters

  • Findings consistent with the CLEOPATRA trial, supporting paclitaxel as a safe and effective alternative to docetaxel, with a different safety profile.

Study design

  • Multicenter, single-group phase 3b PERUSE trial of 1436 patients with HER2+ LR/mBCa receiving investigator-selected taxanes until disease progression or unacceptable toxicity.
  • Primary outcome was safety.
  • Funding: F. Hoffmann LaRoche Ltd.

Key results

  • Paclitaxel-containing therapy (vs docetaxel-containing) was associated with more all-grade peripheral neuropathy (31% vs 16%) but less febrile neutropenia (1% vs 11%) and mucositis (14% vs 25%).
  • At median 52.2 months, median overall PFS was 20.6 (95% CI, 18.9-22.7) months, with similar duration among individual taxanes:
    • Docetaxel 19.6; 95% CI, 16.9-21.8 months.
    • Paclitaxel 23.0; 95% CI, 19.8-25.8 months.
    • Nab-paclitaxel 18.1; 95% CI, 12.2-32.3 months.
  • Overall objective response rate was 80% (95% CI, 78%-82%), with similar rates among individual taxanes:
    • Docetaxel 79%; 95% CI, 75%-82%.
    • Paclitaxel 83%; 95% CI, 79%-86%.
    • Nab-paclitaxel 77%; 95% CI, 64%-88%.

Limitation

  • Nonrandomized design.

Please confirm your acceptance

To gain full access to GPnotebook please confirm:

By submitting here you confirm that you have accepted Terms of Use and Privacy Policy of GPnotebook.

Submit